Research To Practice | Oncology Videos

Latest Episodes:

Acute Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia Jan 07, 2025

Show notes

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

Introduction (0:00)
Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei (2:48)
Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML — Dr Stone (26:52)
Role of FLT3 Inhibitors in AML Management — Dr Perl (49:41)
Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein (1:13:57)
Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang (1:35:50)

CME information and select publications

Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer Jan 03, 2025

Show notes

Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics:

Introduction (0:00)
Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21)
Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36)
Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58)
Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52)
Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24)

CME information and select publications

HER2-Low and HER2-Ultralow Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer Dec 23, 2024

Show notes

Featuring perspectives from Dr Aditya Bardia, Prof Giuseppe Curigliano, Dr Hope S Rugo and Dr Antonio C Wolff, including the following topics:

Introduction (0:00)
Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer — Dr Wolff (2:28)
Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr Bardia (23:16)
Practical Applications of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Metastatic Breast Cancer — Prof Curigliano (51:31)
Future Directions for HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Breast Cancer — Dr Rugo (1:11:57)

CME information and select publications

Multiple Myeloma | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma Dec 21, 2024

Show notes

Featuring perspectives from Dr Sagar Lonial, Prof Philippe Moreau, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:

Introduction (0:00)
Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski (1:26)
Integration of Novel Therapies into the Management of Relapsed/Refractory MM — Dr Richardson (26:53)
Chimeric Antigen Receptor T-Cell Therapy for MM — Dr Raje (48:48)
Bispecific Antibodies for the Treatment of MM — Prof Moreau (1:12:52)
Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial (1:36:32)

CME information and select publications

Chronic Lymphocytic Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia Dec 19, 2024

Show notes

Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics:

Introduction (0:00)
Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44)
Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43)
Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20)
Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52)
Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06)

CME information and select publications

Colorectal and Gastroesophageal Cancers | Cases from the Community: Integrating New Research Findings into Practice Dec 18, 2024

Show notes

Featuring perspectives from Dr Christopher Lieu, moderated by Dr Stephen "Fred" Divers

CME information and select publications

Hepatobiliary Cancers | Cases from the Community: Integrating New Research Findings into Practice Dec 18, 2024

Show notes

Featuring perspectives from Dr Daneng Li, moderated by Dr Stephen "Fred" Divers

CME information and select publications

Gynecologic Cancers | Cases from the Community: Integrating New Research Findings into Practice Dec 17, 2024

Show notes

Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen "Fred" Divers

CME information and select publications

Myelofibrosis | Cases from the Community: Integrating New Research Findings into Practice Dec 17, 2024

Show notes

Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen "Fred" Divers

CME information and select publications

ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2 Dec 16, 2024

Show notes

Featuring an interview with Dr Seth Wander, including the following topics:

Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment
- Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00)
EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer
- Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50)
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer
- Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected